Drug-induced eruptive melanocytic nevi. 2017

Gino A Vena, and Maria Concetta Fargnoli, and Nicoletta Cassano, and Giuseppe Argenziano
a Dermatology and Venereology Private Practice , Bari and Barletta , Italy.

The sudden eruption of melanocytic nevi has been associated with a number of conditions, such as bullous skin diseases, immunodeficiency and immunosuppression. The exact mechanisms leading to the development of eruptive melanocytic nevi are unknown. Areas covered: The aim of this article is to review the literature concerning eruptive melanocytic nevi following the administration of immunosuppressive drugs and other medications. Expert opinion: The literature regarding the development of eruptive nevi in association with pharmacological therapies includes a relatively low number of reports. Prevalence of this phenomenon is likely to be underestimated, thus reporting should be encouraged in order to better define the actual significance and related clinical implications. The development of multiple melanocytic nevi during immunosuppressive treatments highlights the importance of immune system integrity in the regulation of nevi growth. The observation of eruptive nevi as an unexpected effect of targeted therapies for specific types of cancer, including melanoma, provided intriguing hints to understand the mechanisms underlying this paradoxical event. The synergistic role of additional triggers in the occurrence of drug-induced eruptive nevi has not been explored and may be an interesting area of research.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D009508 Nevus, Pigmented A nevus containing melanin. The term is usually restricted to nevocytic nevi (round or oval collections of melanin-containing nevus cells occurring at the dermoepidermal junction of the skin or in the dermis proper) or moles, but may be applied to other pigmented nevi. Nevus, Melanocytic,Nevi, Melanocytic,Nevi, Pigmented,Pigmented Moles,Melanocytic Nevi,Melanocytic Nevus,Pigmented Nevi,Pigmented Nevus
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D012878 Skin Neoplasms Tumors or cancer of the SKIN. Cancer of Skin,Skin Cancer,Cancer of the Skin,Neoplasms, Skin,Cancer, Skin,Cancers, Skin,Neoplasm, Skin,Skin Cancers,Skin Neoplasm
D016867 Immunocompromised Host A human or animal whose immunologic mechanism is deficient because of an immunodeficiency disorder or other disease or as the result of the administration of immunosuppressive drugs or radiation. Immunosuppressed Host,Immunocompromised Patient,Host, Immunocompromised,Host, Immunosuppressed,Hosts, Immunocompromised,Hosts, Immunosuppressed,Immunocompromised Hosts,Immunocompromised Patients,Immunosuppressed Hosts,Patient, Immunocompromised,Patients, Immunocompromised

Related Publications

Gino A Vena, and Maria Concetta Fargnoli, and Nicoletta Cassano, and Giuseppe Argenziano
October 2017, Actas dermo-sifiliograficas,
Gino A Vena, and Maria Concetta Fargnoli, and Nicoletta Cassano, and Giuseppe Argenziano
November 2016, Journal of dermatological case reports,
Gino A Vena, and Maria Concetta Fargnoli, and Nicoletta Cassano, and Giuseppe Argenziano
February 2022, Melanoma research,
Gino A Vena, and Maria Concetta Fargnoli, and Nicoletta Cassano, and Giuseppe Argenziano
January 1998, Klinische Padiatrie,
Gino A Vena, and Maria Concetta Fargnoli, and Nicoletta Cassano, and Giuseppe Argenziano
October 2019, American journal of clinical dermatology,
Gino A Vena, and Maria Concetta Fargnoli, and Nicoletta Cassano, and Giuseppe Argenziano
November 2018, JAAD case reports,
Gino A Vena, and Maria Concetta Fargnoli, and Nicoletta Cassano, and Giuseppe Argenziano
August 1997, Journal of the American Academy of Dermatology,
Gino A Vena, and Maria Concetta Fargnoli, and Nicoletta Cassano, and Giuseppe Argenziano
April 1991, International journal of dermatology,
Gino A Vena, and Maria Concetta Fargnoli, and Nicoletta Cassano, and Giuseppe Argenziano
January 2024, International journal of dermatology,
Gino A Vena, and Maria Concetta Fargnoli, and Nicoletta Cassano, and Giuseppe Argenziano
October 2012, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete,
Copied contents to your clipboard!